ADELAIDE, Australia / RankWire.AI / – Researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have discovered a novel molecular switch that influences the progression of aggressive tumors. The findings, published in EMBO Molecular Medicine, highlight a new approach to addressing triple-negative breast cancer by reactivating a vital regulatory molecule called miR-342. This breakthrough offers potential pathways to prevent life-threatening secondary cancers in organs like the lungs and bones.
Triple-negative breast cancer makes up 10% to 15% of Australia’s roughly 21,000 yearly breast cancer cases but accounts for a disproportionately high number of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, making conventional targeted hormone therapies ineffective. The research team demonstrated that reduced levels of miR-342 lead to an overactive E2F pathway, which promotes the spread of dormant cancer cells and the formation of dangerous secondary tumors throughout the body.
Potential for Diagnostic Biomarker Testing to Identify High-Risk Patients
In pre-clinical experiments, scientists showed that restoring miR-342 levels significantly decreased the metastasis of cancer cells to distant organs. Additionally, the team found that palbociclib, a CDK4/6 inhibitor already approved for hormone receptor-positive breast cancers, substantially suppressed metastatic tumor growth in models with low miR-342 expression. These results imply that assessing miR-342 levels could help clinicians repurpose existing drugs to treat patients at high risk for metastasis.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, co-senior author, confirmed that preventing metastasis remains the key obstacle in managing aggressive breast cancers. Gregory pointed out that because palbociclib targets the hyperactive E2F pathway, administering the drug after cancer cells have spread can stop microscopic deposits from expanding. Instead of only aiming to reduce primary tumor size, this approach focuses on stopping microscopic secondary cancers from developing into life-threatening conditions.
miR-342 Functions as a Master Regulator for Cancer-Related Genes
The research team emphasized that the biological diversity of triple-negative breast cancer has historically complicated the development of universal targeted treatments. By identifying a specific vulnerability shared by a particular patient subgroup, this study paves the way for personalized therapies. As Australian scientists uncover a promising new method to combat triple-negative breast cancer, efforts are underway to validate these findings using patient-derived models ahead of clinical testing.
Medical oncologists and cancer research organizations throughout Australia have welcomed the new insights, emphasizing the urgent need for expanded treatment options when primary therapies are insufficient. The research team intends to collaborate with global clinical networks to expedite biomarker screening protocols. Confirming the effectiveness of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapies during early intervention stages.